Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06454955
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-05-30
Brief Title:
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
Study of B7-H3 Mediated Tumor Immune Response Using a Whole-Body Kinetic Approach in Whole-Body PET
Status:
RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Based on 68GaB7H3 Affibody-BCH this study investigates its radioactive uptake and imaging capabilities in tumor patients with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression Utilizing whole-body PET technology the pharmacokinetic dynamics of 68GaB7H3 Affibody-BCH are examined to ascertain its pharmacological characteristics Ultimately this research establishes a framework for pharmacokinetic analysis using whole-body PET
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None